 |
 |
|
Home |
Current Issue |
Past Issues |
Audio/Video |
CME |
Collections |
In the Clinic |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
|
Articles 
Mark Pimentel, Sandy Park, James Mirocha, Sunanda V. Kane, and Yuthana Kong In this double-blind trial, 87 patients with the irritable bowel syndrome were randomly assigned to either rifaximin (400 mg 3 times daily) or placebo for 10 days. Over a 10-week follow-up period, the rifaximin recipients reported global improvements in overall symptoms and less bloating more frequently than the placebo recipients. No major differences in abdominal pain, diarrhea, or constipation were observed between the groups.
Thomas A. Peterman, Lin H. Tian, Carol A. Metcalf, Catherine L. Satterwhite, C. Kevin Malotte, Nettie DeAugustine, Sindy M. Paul, Helene Cross, Cornelis A. Rietmeijer, John M. Douglas, Jr. for the RESPECT-2 Study Group* Among patients treated for sexually transmitted infections, 25.8% of women and 14.7% of men acquired 1 or more new infections with Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis during 1 year of follow-up. Approximately 66% of reinfections were asymptomatic.
Lesley M. Roberts, Helen Pattison, Andrea Roalfe, Jayne Franklyn, Sue Wilson, F.D. Richard Hobbs, and James V. Parle The authors studied 5868 general practice patients 65 years of age or older with a detailed medical history, thyroid tests, and standardized tests of cognition and mood. Two hundred ninety-five patients had subclinical thyroid dysfunction. The authors found no association between subclinical thyroid dysfunction and anxiety, depression, or cognitive impairment.
Victor D. Rosenthal, Dennis G. Maki, Reinaldo Salomao, Carlos Álvarez Moreno, Yatin Mehta, Francisco Higuera, Luis E. Cuellar, Özay Akan Arikan, Rédouane Abouqal, Hakan Leblebicioglu for the International Nosocomial Infection Control Consortium* Prospective surveillance of 21 069 patients hospitalized in 55 intensive care units in 46 hospitals in Central and South America, India, Morocco, and Turkey showed high rates (22.5 infections per 1000 intensive care unit days) of device-associated infections. Infections included ventilator-associated pneumonia (41%), central venous catheter–related bloodstream infections (30%), and catheter-associated urinary tract infections (29%).
Improving Patient Care
Kaveh G. Shojania, Kathlyn E. Fletcher, and Sanjay Saint This paper, the last in the Quality Grand Rounds series, discusses a patient who died after admission to a teaching hospital with a mild episode of acute pancreatitis. This case, in which diagnostic delay was compounded by poor communication, highlights the hazards of patient handoffs as well as the importance of clear communication techniques and knowing when to ask for help. The discussion also shows the vicious circle that results when attending physicians fail to provide effective supervision.
Updates
Elliot Rapaport This Update in Cardiology features 13 articles published in 2005, focusing on hypertension, diabetes and cardiovascular disease, acute myocardial infarction, and heart failure.
Reviews
Thomas C. Luke, Edward M. Kilbane, Jeffrey L. Jackson, and Stephen L. Hoffman This review of 8 controlled studies published in English-language medical literature between 1918 to 1925 found that transfusion with influenza-convalescent human blood products may have reduced risk for death in hospitalized patients with Spanish influenza complicated by pneumonia.
Henry H. Ting, Eric H. Yang, and Charanjit S. Rihal Optimal treatment for ST-segment elevation myocardial infarction depends on early diagnosis and rapid selection of the appropriate reperfusion strategy. Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy at PCI-capable hospitals, but transferring patients to a hospital that does primary PCI may cause clinically important delays. The authors present a systematic, evidence-based approach to selecting a reperfusion strategy.
Editorials
Douglas A. Drossman In this issue, Pimentel and colleagues evaluated the efficacy of a newer broad-spectrum nonabsorbable antibiotic, rifaximin, for the irritable bowel syndrome (IBS), measuring clinical response for up to 10 weeks after treatment. They concluded that rifaximin treatment for 10 days showed greater global improvement than placebo. Demonstrating sustained benefit from a short course of an antibiotic in unselected patients with IBS is certainly novel and important. However, several methodologic concerns stand in the way of drawing firm conclusions from the study.
Robert M. Wachter, Kaveh G. Shojania, Amy J. Markowitz, Mark Smith, and Sanjay Saint This issue contains the 13th and final article in the Quality Grand Rounds series. We end the series with profound thanks to the many physicians, nurses, pharmacists, administrators, and patients who shared their stories with us in the hope that doing so might prevent another error. We hope that the cases have not only been useful for their specific content but that they have encouraged institutions and providers to use their own cases to ensure that patients receive safe, high-quality care.
John J. Treanor In this issue, Luke and colleagues analyze 8 studies that evaluated the effects of therapy with serum or plasma from convalescent patients on the course of clinically diagnosed influenza pneumonia during the 1918 Spanish influenza pandemic. The quality of these studies was relatively poor by modern standards. However, all 8 supported the hypothesis that passive serotherapy was useful in treating Spanish influenza. Would a similar approach be effective and feasible in the event of a pandemic of H5N1 influenza?
Letters Green Tea, Coffee, and Diabetes
Correction: Patients' Global Ratings of Their Health Care Are Not Associated with the Technical Quality of Their Care
| |||||||||||||||||||||||||||||||||||||||
In this Issue
Articles
Previous Issue